Atsena Therapeutics
Dan Yoon has worked in the medical field since 2015. Dan began as an Ophthalmology Resident at the University of Illinois at Chicago, where they were also a Mentor/Advisor at the UIC Innovation Center developing a novel drug delivery contact lens. Dan also conducted clinical research, including a meta-analysis of sequential glaucoma drainage device implantation and predictors of success for ptosis repair. In 2016, they became a Consultant at MAG Optics Inc. In 2018, they became an Assistant Professor of Ophthalmology at UMass Memorial Medical Center. In 2020, they took on the role of Associate Medical Director at Biogen. Most recently, in 2021, they became Medical Director at Atsena Therapeutics.
Dan Yoon obtained their MD from NYU Grossman School of Medicine, followed by a Global Clinical Scholars Research Training Program from Harvard Medical School. Dan also holds a BA in Biology from Swarthmore College.
This person is not in any offices
Atsena Therapeutics
Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. They have an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Their additional pipeline of leading preclinical assets is powered by an adeno-associated virus (AAV) technology platform tailored to overcome significant hurdles presented by inherited retinal disease.